Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3677456 | 0.89 | SMN1; SMN2 (0.34) | CYP1A2CYP3A4CYP2D6TSHRCLK4 | |
| SCHEMBL3671783 | 0.87 | ALDH1A1 (0.32) | CYP1A2CYP3A4CYP2D6TSHRCLK4 | |
| SCHEMBL3671142 | 0.86 | KDM4E (0.45) | CYP1A2TSHRMAPK1KDM4EGAA | |
| SCHEMBL3674927 | 0.85 | GRIN2B (0.37) | CYP1A2CYP3A4CYP2D6TSHRCLK4 | |
| SCHEMBL3673565 | 0.72 | NPC1 (0.37) | ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL3671544 | 0.72 | IDO1 (0.33) | — | |
| SCHEMBL3677454 | 0.71 | ALDH1A1 (0.40) | TSHRALDH1A1KDM4EGAAMAPT | |
| SCHEMBL3671779 | 0.69 | KMT5B (0.40) | CYP1A2ALDH1A1MAPK1MAPT | |
| SCHEMBL29127243 | 0.63 | ALDH1A1 (0.49) | CYP3A4CYP2D6ALDH1A1KDM4EGAA | |
| SCHEMBL5202907 | 0.62 | MAPT (0.47) | CYP1A2CYP3A4CYP2D6TSHRCLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966225-B1 | TRANSITION METAL COMPLEXES AND PREPARATION METHODS THEREOF | LG CHEMICAL LTD (KR) | 2013-12-25 | — | — | EP | disclosed |
| EP-1966223-B1 | CATALYST COMPOSITION COMPRISING GROUP 4 TRANSITION METAL COMPLEXES AND METHOD FOR PREPARING POLYOLEFINS USING THE SAME | LG CHEMICAL LTD (KR) | 2013-08-14 | — | — | EP | disclosed |
| US-7807762-B2 | Catalyst composition comprising Group 4 transition metal complexes and method for preparing polyolefins using the same | LG CHEM, LTD. (KR) | 2010-10-05 | — | — | US | disclosed |
| US-7678933-B2 | Transition metal complexes and preparation methods thereof | LG CHEM, LTD. (KR) | 2010-03-16 | — | — | US | disclosed |
| US-20090030221-A1 | Transition Metal Complexes and Preparation Methods Thereof | LG CHEM, LTD (KR) | 2009-01-29 | — | — | US | disclosed |
| US-20090005525-A1 | Catalyst Composition Comprising Group 4 Transition Metal Complexes and Method for Preparing Polyolefins Using the Same | LG CHEM , LTD. (KR) | 2009-01-01 | — | — | US | disclosed |
| EP-1966223-A1 | CATALYST COMPOSITION COMPRISING GROUP 4 TRANSITION METAL COMPLEXES AND METHOD FOR PREPARING POLYOLEFINS USING THE SAME | LG Chem. Ltd. (KR) | 2008-09-10 | — | — | EP | disclosed |
| EP-1966225-A1 | TRANSITION METAL COMPLEXES AND PREPARATION METHODS THEREOF | LG Chem, Ltd. (KR) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007078134-A1 | TRANSITION METAL COMPLEXES AND PREPARATION METHODS THEREOF | LG CHEM. LTD. (KR) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007078133-A1 | CATALYST COMPOSITION COMPRISING GROUP 4 TRANSITION METAL COMPLEXES AND METHOD FOR PREPARING POLYOLEFINS USING THE SAME | LG CHEM. LTD. (KR) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030221-A1 | Transition Metal Complexes and Preparation Methods Thereof | PICALM, TEC, PPIP5K2 | CYP1A2 3397/4885CYP3A4 1200/4885CYP2D6 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.